Madrigal Pharmaceuticals (MDGL) Given News Sentiment Score of -0.04

Press coverage about Madrigal Pharmaceuticals (NASDAQ:MDGL) has been trending somewhat negative recently, according to Accern Sentiment Analysis. Accern identifies negative and positive news coverage by monitoring more than 20 million blog and news sources. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Madrigal Pharmaceuticals earned a news sentiment score of -0.04 on Accern’s scale. Accern also assigned headlines about the biopharmaceutical company an impact score of 47.040311044037 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the near term.

Here are some of the news headlines that may have impacted Accern Sentiment Analysis’s analysis:

Shares of Madrigal Pharmaceuticals (NASDAQ:MDGL) opened at $113.81 on Friday. Madrigal Pharmaceuticals has a 12-month low of $13.09 and a 12-month high of $154.75. The firm has a market capitalization of $1,700.49, a PE ratio of -44.81 and a beta of 1.32.

Madrigal Pharmaceuticals (NASDAQ:MDGL) last released its quarterly earnings results on Tuesday, March 13th. The biopharmaceutical company reported ($0.67) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.70) by $0.03. analysts forecast that Madrigal Pharmaceuticals will post -3.24 earnings per share for the current fiscal year.

Several equities research analysts recently issued reports on the company. Zacks Investment Research lowered Madrigal Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Friday, February 2nd. Evercore ISI reissued an “outperform” rating and set a $175.00 price objective (up previously from $140.00) on shares of Madrigal Pharmaceuticals in a research note on Thursday, February 8th. Cowen assumed coverage on Madrigal Pharmaceuticals in a research note on Wednesday, February 28th. They set an “outperform” rating for the company. Roth Capital lifted their price objective on Madrigal Pharmaceuticals from $170.00 to $210.00 and gave the company a “buy” rating in a research note on Friday, February 9th. Finally, HC Wainwright raised their price target on Madrigal Pharmaceuticals from $105.00 to $156.00 and gave the company a “buy” rating in a research report on Tuesday, January 30th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and six have given a buy rating to the company’s stock. Madrigal Pharmaceuticals currently has an average rating of “Buy” and an average target price of $154.20.

WARNING: “Madrigal Pharmaceuticals (MDGL) Given News Sentiment Score of -0.04” was originally published by The Lincolnian Online and is the property of of The Lincolnian Online. If you are viewing this report on another website, it was illegally copied and republished in violation of U.S. and international copyright law. The original version of this report can be accessed at

Madrigal Pharmaceuticals Company Profile

Madrigal Pharmaceuticals, Inc, formerly Synta Pharmaceuticals Corp., is a clinical-stage biopharmaceutical company. The Company focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular-metabolic diseases and nonalcoholic steatohepatitis (NASH). The Company’s lead product, MGL-3196, is a Phase II-ready once-daily, oral, liver-directed selective thyroid hormone receptor-b (THR-b) agonist for the treatment of NASH, and heterozygous and homozygous familial hypercholesterolemia (FH).

Insider Buying and Selling by Quarter for Madrigal Pharmaceuticals (NASDAQ:MDGL)

Receive News & Ratings for Madrigal Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Madrigal Pharmaceuticals and related companies with's FREE daily email newsletter.

Leave a Reply